On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. Also Read: Jim Cramer Says Eli ...
Shares of the company fell more than 7% on Tuesday as analysts chewed over bone density loss data from an early-stage trial on the injection. One analyst said the additional data suggests a new ...
GLP-1 drugs are driving major weight loss trends, but doctors warn that rapid weight loss may affect nutrition, bone density, heart health, and blood sugar balance.